agilon health, inc. (AGL) Financial Statements
agilon health, inc. (AGL) reported trailing twelve-month revenue of $5.9B (up 0.3% year on year) and net income of -$232.2M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$85.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AGLagilon health, inc.Follow AGL — free
—
Price chart with a free account
- Market cap
- 1.5B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 1.52 | 2.39 | 4.32 | 6.06 | 5.93 | 5.92 | |
| Gross profit | — | — | 0.05 | — | — | — | |
| Operating income | -0.37 | -0.11 | -0.23 | -0.29 | -0.46 | -0.31 | |
| Pre-tax income | -0.38 | -0.09 | -0.19 | -0.25 | -0.40 | -0.25 | |
| Income tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net income | -0.41 | -0.11 | -0.26 | -0.26 | -0.39 | -0.23 | |
| Diluted EPS ($) | — | -5.50 | -12.00 | -15.25 | -24.50 | -13.49 | |
| Diluted shares (bn) | — | 0.016 | 0.016 | 0.016 | 0.017 | — |
USD billions · SEC XBRL
agilon health, inc. — questions
- What is agilon health, inc.'s revenue?
- $5.9B over the twelve months to 2026-06-30, up 0.3% year on year, from its 10-Q and 10-K filings.
- What is agilon health, inc.'s net income?
- -$232.2M over the twelve months to 2026-06-30.
- What is agilon health, inc.'s free cash flow?
- -$85.0M over the twelve months to 2026-06-30.
- What are agilon health, inc.'s diluted earnings per share?
- $-13.49 over the twelve months to 2026-06-30.
Every figure on this page comes from agilon health, inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.